Tafinlar and Panic attack - a phase IV clinical study of FDA data

Summary:

Panic attack is reported as a side effect among people who take Tafinlar (dabrafenib mesylate), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Mekinist, and have Metastatic malignant melanoma.

The phase IV clinical study analyzes which people have Panic attack when taking Tafinlar. It is created by eHealthMe based on reports of 16,296 people who have side effects when taking Tafinlar from the FDA, and is updated regularly.

What is Tafinlar?

Tafinlar has active ingredients of dabrafenib mesylate. eHealthMe is studying from 16,304 Tafinlar users. Check the latest studies of Tafinlar.

What is Panic attack?

Panic attack is found to be associated with 2,359 drugs and 2,081 conditions by eHealthMe. Check the latest studies of Panic attack.

On Jun, 22, 2026

16,296 people reported to have side effects when taking Tafinlar.
Among them, 11 people (0.07%) have Panic attack.

Among these 11 people:

How long have people been on Tafinlar when they have Panic attack? *

What is the gender of people who have Panic attack when taking Tafinlar? *

female: 72.73 %
male: 27.27 %

What is the age of people who have Panic attack when taking Tafinlar? *

What are other drugs people take besides Tafinlar? *

Mekinist: 11 people, 100.00%
Dimenhydrinate: 3 people, 27.27%
Cefadroxil: 3 people, 27.27%

What are other side effects people have besides Panic attack? *

Rashes (redness): 8 people, 72.73%
Muscle Aches (muscle pain): 6 people, 54.55%
Hyperkeratosis (thickening of the outer layer of the skin): 6 people, 54.55%
Chills (felling of cold): 6 people, 54.55%
Arrhythmias (irregular heartbeat): 5 people, 45.45%
Diarrhea: 5 people, 45.45%
Dizziness: 5 people, 45.45%
Weakness: 5 people, 45.45%
Fatigue (feeling of tiredness): 5 people, 45.45%
Back Pain: 4 people, 36.36%

What are the existing conditions these people have? *

Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 6 people, 54.55%
Malignant Melanoma (skin cancer rises from melancytes): 3 people, 27.27%
Erysipelas (bacterial skin infection): 3 people, 27.27%
Neoplasm Malignant (cancer tumour): 2 people, 18.18%

* Approximation only. Some reports may have incomplete information.

Do you take Tafinlar and have Panic attack?

- Check whether Panic attack is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tafinlar:

Tafinlar (16,304 reports)

Panic attack treatments and more:

Panic attack (65,704 reports)

Browse all side effects of Tafinlar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Panic attack:

Panic attack (2,359 drugs)

Browse all the conditions that are associated with Panic attack:

Panic attack (2,081 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dabrafenib mesylate (the active ingredients of Tafinlar) and Tafinlar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.